TransMedics Group Cash Flow Statement
NASDAQ: TMDXHealth CareBiotechnology: Electromedical & Electrotherapeutic ApparatusUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
TransMedics Group free cash flow
In fiscal 2025, TransMedics Group generated $192.8 million of operating cash flow and spent $59.3 million on capital expenditures. That left free cash flow of $133.6 million, a free-cash-flow margin of 22.1% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
TransMedics Group cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-28 | FY 20182018-12-29 |
|---|---|---|---|---|---|---|---|---|
| Net Income | 190.29M | 35.46M | -25.03M | -36.23M | -44.22M | -28.70M | -33.55M | -23.76M |
| Net Income growth (YoY) | +436.58% | — | — | — | — | — | — | — |
| Depreciation & Amortization | 27.18M | 19.76M | 8.18M | 3.48M | 1.82M | 1.58M | 1.22M | 769.00K |
| Stock-Based Compensation | 36.86M | 33.22M | 19.79M | 10.32M | 6.88M | 2.41M | 854.00K | 144.00K |
| Change in Working Capital | 3.60M | -50.52M | -56.97M | -30.45M | -2.11M | -8.47M | -3.73M | -6.34M |
| Operating Cash Flow | 192.84M | 48.80M | -13.03M | -45.82M | -28.86M | -30.27M | -32.29M | -25.98M |
| Capital Expenditures | -59.25M | -129.74M | -151.85M | -11.91M | -3.52M | -455.00K | -165.00K | -418.00K |
| Investing Cash Flow | -59.25M | -129.30M | -193.95M | 54.51M | 29.27M | -41.60M | -60.50M | 12.31M |
| Debt Issued | — | — | — | 58.51M | — | — | — | 33.44M |
| Debt Repaid | — | — | — | -36.05M | — | — | — | -9.08M |
| Financing Cash Flow | 16.86M | 22.87M | 400.42M | 167.93M | 1.39M | 75.55M | 92.72M | 22.06M |
| Net Change in Cash | 151.72M | -58.16M | 193.63M | 175.60M | 999.00K | 4.49M | -149.00K | 8.30M |
| Free Cash Flow | 133.59M | -80.94M | -164.88M | -57.72M | -32.38M | -30.72M | -32.45M | -26.40M |
This table shows 8 annual periods of TransMedics Group's cash flow statement, from FY 2025 back to FY 2018, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow TMDX's reporting calendar. What is a cash flow statement?